CN102036561A - 蛋白激酶调节剂 - Google Patents

蛋白激酶调节剂 Download PDF

Info

Publication number
CN102036561A
CN102036561A CN2009801155149A CN200980115514A CN102036561A CN 102036561 A CN102036561 A CN 102036561A CN 2009801155149 A CN2009801155149 A CN 2009801155149A CN 200980115514 A CN200980115514 A CN 200980115514A CN 102036561 A CN102036561 A CN 102036561A
Authority
CN
China
Prior art keywords
optionally substituted
compound
alkyl
group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801155149A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·C·乔
马斯塔法·哈达科
约翰尼·Y·纳加萨瓦
法布里斯·皮埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CN102036561A publication Critical patent/CN102036561A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN2009801155149A 2008-02-29 2009-02-28 蛋白激酶调节剂 Pending CN102036561A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6784508P 2008-02-29 2008-02-29
US61/067,845 2008-02-29
US10390808P 2008-10-08 2008-10-08
US61/103,908 2008-10-08
PCT/US2009/035609 WO2009108912A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Publications (1)

Publication Number Publication Date
CN102036561A true CN102036561A (zh) 2011-04-27

Family

ID=41016490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801155149A Pending CN102036561A (zh) 2008-02-29 2009-02-28 蛋白激酶调节剂

Country Status (8)

Country Link
US (2) US8168651B2 (enExample)
EP (1) EP2259678A4 (enExample)
JP (1) JP2011515337A (enExample)
CN (1) CN102036561A (enExample)
AU (1) AU2009219154A1 (enExample)
CA (1) CA2716755A1 (enExample)
MX (1) MX2010009445A (enExample)
WO (1) WO2009108912A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
WO2019191896A1 (en) * 2018-04-03 2019-10-10 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113302184A (zh) * 2018-11-15 2021-08-24 日本新药株式会社 1,3,4-噁二唑啉酮化合物和药物
CN113444085A (zh) * 2020-03-26 2021-09-28 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN114369096A (zh) * 2020-10-16 2022-04-19 上海迪诺医药科技有限公司 三杂环衍生物、其药物组合物及应用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
US20100267753A1 (en) * 2009-04-17 2010-10-21 Mustapha Haddach Methods of treating disorders associated with protein kinase ck2 activity
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
SG178552A1 (en) * 2009-08-26 2012-03-29 Cylene Pharmaceuticals Inc Condensed quinolines as protein kinase modulators
PE20121150A1 (es) * 2009-09-03 2012-08-27 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
US20110065712A1 (en) * 2009-09-16 2011-03-17 Cylene Pharmaceuticals , Inc. Tricyclic compounds and pharmaceutical uses thereof
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP3444242A3 (en) 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
EP2521782B1 (en) * 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
HRP20171610T1 (hr) 2012-07-04 2018-03-23 Rhizen Pharmaceuticals S.A. Selektivni inhibitori pi3k delta
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CA2897333C (en) 2013-01-15 2021-07-06 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AU2018392816B2 (en) 2017-12-22 2023-04-20 HiberCell Inc. Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
GB201902759D0 (en) 2019-02-28 2019-04-17 Benevolentai Bio Ltd Compositions and uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
EP4126846A1 (en) 2020-03-30 2023-02-08 Senhwa Biosciences, Inc. Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2023225586A2 (en) * 2022-05-19 2023-11-23 4M Therapeutics Inc. Novel azaphenantrhene derivatives as inhibitors of glycogen synthase kinase 3 for therapeutic use
IL322451A (en) * 2023-02-03 2025-09-01 Mirati Therapeutics Inc Substituted tricyclic compounds
US11987581B1 (en) 2023-12-19 2024-05-21 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors
US12024518B1 (en) 2023-12-20 2024-07-02 King Faisal University Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US11964974B1 (en) 2024-01-08 2024-04-23 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
WO2007022268A2 (en) * 2005-08-16 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2007070319A2 (en) * 2005-12-13 2007-06-21 Wyeth Dibenzonaphthyridine derivatives and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
WO2008042282A2 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
WO2007022268A2 (en) * 2005-08-16 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2007070319A2 (en) * 2005-12-13 2007-06-21 Wyeth Dibenzonaphthyridine derivatives and methods of use thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
CN110945001B (zh) * 2018-04-03 2022-11-25 硕英生医股份有限公司 Fms样酪氨酸激酶抑制剂
WO2019191896A1 (en) * 2018-04-03 2019-10-10 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
CN110945001A (zh) * 2018-04-03 2020-03-31 三日月生技股份有限公司 Fms样酪氨酸激酶抑制剂
CN113302184A (zh) * 2018-11-15 2021-08-24 日本新药株式会社 1,3,4-噁二唑啉酮化合物和药物
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113444085A (zh) * 2020-03-26 2021-09-28 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
WO2021190142A1 (zh) * 2020-03-26 2021-09-30 东南大学 一类抗肿瘤化合物及其制备与用途
WO2021190076A1 (zh) * 2020-03-26 2021-09-30 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN114369096A (zh) * 2020-10-16 2022-04-19 上海迪诺医药科技有限公司 三杂环衍生物、其药物组合物及应用
WO2022078480A1 (zh) * 2020-10-16 2022-04-21 上海迪诺医药科技有限公司 三杂环衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
CA2716755A1 (en) 2009-09-03
US20120208792A1 (en) 2012-08-16
US20090239859A1 (en) 2009-09-24
EP2259678A4 (en) 2011-07-27
US8168651B2 (en) 2012-05-01
WO2009108912A1 (en) 2009-09-03
AU2009219154A1 (en) 2009-09-03
MX2010009445A (es) 2011-05-25
EP2259678A1 (en) 2010-12-15
JP2011515337A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
US8168651B2 (en) Protein kinase modulators
US10844032B2 (en) Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors
RU2525116C2 (ru) Гетероциклические соединения и способы применения
US8293738B2 (en) Indazole inhibitors of kinase
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
EP2435435B1 (en) Pyrimidine inhibitors of kinase activity
US8354422B2 (en) Pyrimidine inhibitors of kinase activity
CA2943815A1 (en) Substituted indole mcl-1 inhibitors
US8486933B2 (en) Pyrimidine inhibitors of kinase activity
US20130225589A1 (en) Pyridopyrimidinone inhibitors of kinases
MX2012013196A (es) Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.
US20130023555A1 (en) Kinase inhibitor with improved solubility profile

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110427